Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Many proteins in biology exist in more than one form. Examples include ion channels that control electrical activity in the body, metabolic enzymes, and proteins called transcription factors that help control gene expression. In immune cells, one family of transcription factors, the NFAT family, is important in cell differentiation and activation. NFATs control the expression of genes that produce signaling molecules that help co-ordinate the activities of different immune cells and defective NFAT activation is linked to a range of human diseases. Immune cells express several different NFATs, and it has proved difficult to control selectively the activity of each protein.

Professor Anant Parekh’s group in DPAG have discovered how different NFAT proteins are controlled in cells. Their new findings, published in this month’s Molecular Cell (58, 232-243), demonstrate that different patterns of signal recruit different NFAT proteins. Their results open up the possibility for drugs aimed at targeting one NFAT protein and not another, allowing for selective therapeutic control of an immune response.

Read more (Department of Physiology, Anatomy and Genetics website)

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

Clinical Trials Coronavirus COVID-19 General Research

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19.

Ancient gene mutation found to cause rare hereditary condition

General Research

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).